Innoviva (INVA) Share-based Compensation (2010 - 2026)
Innoviva (INVA) reported Share-based Compensation of $2.6 million for Q1 2026, up 19.56% on a YoY basis from $2.1 million in Q1 2025, and up 7.86% quarter-over-quarter from $2.4 million in Q3 2025.
Innoviva (INVA) Share-based Compensation (2010 - 2026) Analysis & Trends
Innoviva has reported Share-based Compensation for 17 years, with the latest figure at $2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 19.56% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (up 38.96% YoY), and the FY2025 full-year result was $9.5 million, up 48.29% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.6 million, up from $2.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $3.7 million in Q3 2022, with the low at $954000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $1.9 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 585.79% — and 2023, when it slumped 61.21%.
- Innoviva's Share-based Compensation stood at $3.7 million in 2022, then tumbled by 61.21% to $1.4 million in 2023, then increased by 11.17% to $1.6 million in 2024, then jumped by 48.47% to $2.4 million in 2025, then advanced by 7.86% to $2.6 million in 2026.
- The last three Share-based Compensation figures came in at $2.6 million (Q1 2026), $2.4 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 26.47 Mn |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn | 2.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.57 Mn |
| Mar 31, 2026 | 2.57 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Mar 31, 2023 | 1.60 Mn |